Company intelligence / Profile preview

Cyxone

Malmö, Skåne County, Swedencyxone.com ↗

Ownership: Private
Employees: ~3
Development stage: Phase 2

Overview

Cyxone developed two main clinical-stage drug candidates targeting autoimmune diseases. Rabeximod reached phase II trials in rheumatoid arthritis, while T20K completed phase I studies in multiple sclerosis. Both programs aimed to offer safer, more effective oral therapies compared to existing treatments. The company’s patent position was strengthened through collaboration with the Medical University of Vienna regarding T20K technology. As of late 2024, the company appears inactive on public markets.

Therapeutic areas: ImmunologyNeurology
Modalities: Small moleculeCyclotide-based drugPeptide
Industry: Biotech

Drug pipeline

2 assets

rabeximod

1 more asset in the full pipeline.

Request access →

Partnerships

Medical University of Vienna

Beyond the preview

Go deeper on Cyxone.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyxone.

Explore the full profile